What Are Novavax's Long-Term Prospects?

Last year, Novavax (NASDAQ: NVAX) was one of the strongest stocks in the entire  market. The micro cap ran up from $4 a share in January all the way to $119 in December. Then in 2021, the stock almost tripled after Novavax reported positive phase 3 data in its U.K. study for a COVID-19 vaccine. After hitting $330 a share, investors were whipsawed as the stock price dropped to $149.

Is Novavax stock a buy today? Corinne Cardina, the Bureau Chief for Healthcare and Cannabis at Fool.com, and Motley Fool contributor Taylor Carmichael discuss this vaccine specialist. This segment was recorded live on March 5.

Continue reading

Source Fool.com